Neurofibromatosis Epidemiology Forecast, 2030

April 16 17:50 2020
Neurofibromatosis Epidemiology Forecast, 2030

DelveInsight Business Research LLP
DelveInsight’s ‘Neurofibromatosis – Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Neurofibromatosis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

DelveInsight’s ‘Neurofibromatosis – Epidemiology Forecast to 2030‘ report delivers an in-depth understanding of the disease, historical and forecasted Neurofibromatosis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Some of the key facts of the report:
1. Neurofibromatosis has been categorized into three distinct types:- NF1, NF2 and Schwannomatosis.
2. Neurofibromatosis (NF1) is the most common neurofibromatosis, occurring in 1 in 3,000 to 4,000 individuals in the United States.
3. NF1 occurs in one in every 3,000 children born.
4. NF2 is a rarer type, occurring in 1:25,000 people worldwide.
5. One of the types is Schwannomatosis, which occurs in 1:40,000 people.

The key benefits of the report:
1. Neurofibromatosis market report covers a descriptive overview and comprehensive insight of the Neurofibromatosis epidemiology and Neurofibromatosis market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Neurofibromatosis market report provides insights on the current and emerging therapies.
3. Neurofibromatosis market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. Neurofibromatosis market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Neurofibromatosis market.

Scope of the Report:
1. The Neurofibromatosis report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
2. The Neurofibromatosis Epidemiology Report and Model provide an overview of the risk factors and global trends of Neurofibromatosis in the seven major markets (7MM:US, France, Germany, Italy, Spain, UK, and Japan)
3. The report provides insight about the historical and forecasted patient pool of Neurofibromatosis in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
4. The report helps to recognize the growth opportunities in the 7MM with respect to the patient population
5. The report assesses the disease risk and burden and highlights the unmet needs of Neurofibromatosis
6. The report provides the segmentation of the Neurofibromatosis epidemiology

Report Highlights:
1. 11-Year Forecast of Neurofibromatosis epidemiology
2. 7MM Coverage
3. Total Cases of Neurofibromatosis
4. Total Cases of Neurofibromatosis according to segmentation
5. Diagnosed cases of Neurofibromatosis

Request for sample pages:

Table of contents:

1. Key Insights 

2. Executive Summary of Neurofibromatosis

3. Neurofibromatosis: Disease Background and Overview

3.1. Introduction

3.2. Sign and Symptoms

3.3. Pathophysiology

3.4. Risk Factors

3.5. Diagnosis

4. Patient Journey

5. Epidemiology and Patient Population

5.1. Epidemiology Key Findings

5.2. Assumptions and Rationale: 7MM

5.3. Epidemiology Scenario: 7MM

5.3.1. Neurofibromatosis Epidemiology Scenario in the 7MM (2017- 2030)

5.4. United States Epidemiology

5.4.1. Neurofibromatosis Epidemiology Scenario in the United States (2017- 2030)

5.5. EU-5 Country-wise Epidemiology

5.5.1. Germany Epidemiology Neurofibromatosis Epidemiology Scenario in Germany (2017- 2030)

5.5.2. France Epidemiology Neurofibromatosis Epidemiology Scenario in France (2017- 2030)

5.5.3. Italy Epidemiology Neurofibromatosis Epidemiology Scenario in Italy (2017- 2030)

5.5.4. Spain Epidemiology Neurofibromatosis Epidemiology Scenario in Spain (2017- 2030)

5.5.5. United Kingdom Epidemiology Neurofibromatosis Epidemiology Scenario in the United Kingdom (2017-2030)

5.6. Japan Epidemiology

5.6.1. Neurofibromatosis Epidemiology Scenario in Japan (2017- 2030)

6. Treatment Algorithm, Current Treatment, and Medical Practices

6.1. Neurofibromatosis Treatment and Management

6.2. Neurofibromatosis Treatment Algorithm

7. KOL Views

8. Unmet Needs

9.  Appendix

9.1. Bibliography

9.2. Report Methodology

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight

*The table of contents is not exhaustive; will be provided in the final report

About DelveInsight:
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Contact us:
Shruti Thakur

[email protected]

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States